Propranolol can take the edge off several alcohol withdrawal symptoms, particularly the rapid heartbeat, elevated blood pressure, tremor, and anxiety that come from a surge of adrenaline-like chemicals in the brain. But it does not protect against the most dangerous complications of withdrawal, including seizures and delirium tremens, so clinical guidelines consistently recommend it only as an add-on to other medications rather than a treatment used on its own.
Why Alcohol Withdrawal Feels Like an Adrenaline Emergency
Alcohol, used heavily over time, suppresses the central nervous system. When that suppression is suddenly removed, the brain overcorrects in the other direction. One major part of this rebound is a flood of norepinephrine, the chemical closely related to adrenaline that drives your fight-or-flight response. Studies measuring norepinephrine in the cerebrospinal fluid of people going through withdrawal found levels that were substantially elevated compared to recovery, dropping as symptoms improved.1JAMA Neurology. CSF Levels of Norepinephrine During Alcohol Withdrawal The severity of withdrawal symptoms tracks with how much norepinephrine the body releases: more norepinephrine, worse symptoms.2PubMed. Alcohol withdrawal and noradrenergic function
This norepinephrine surge is what creates the constellation of symptoms that many people experience during withdrawal: a pounding or racing heart, high blood pressure, profuse sweating, shakiness, and intense anxiety or a sense of impending doom. These are essentially the same symptoms you would feel during a panic attack or extreme stress, because the same chemical system is driving them.3PubMed Central. Neurochemical mechanisms of alcohol withdrawal But the norepinephrine system is only one part of the withdrawal picture. Alcohol also disrupts the balance between excitatory and inhibitory signaling in the brain, and that imbalance is responsible for the more dangerous complications like seizures, hallucinations, and delirium tremens. This distinction matters a great deal when it comes to understanding what propranolol can and cannot do.
What Propranolol Does During Withdrawal
Propranolol is a beta-blocker, a class of drug designed to block the receptors that norepinephrine and adrenaline act on. In the context of withdrawal, this means it directly counteracts many of the most physically uncomfortable symptoms. It slows the heart rate, lowers blood pressure, reduces tremor, and dials down that wired, jittery feeling.
A double-blind trial comparing propranolol head-to-head with diazepam (a standard benzodiazepine) in people experiencing moderate uncomplicated alcohol withdrawal found the two drugs were equally effective at reducing both the physical symptoms and the anxiety of withdrawal over a 15-day treatment period.4Biomedicine & Pharmacotherapy. Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam Another controlled trial also showed improvement in blood pressure, pulse, and withdrawal tremor in patients receiving propranolol.5PubMed. Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial These results are worth knowing because they show propranolol genuinely works for certain symptoms. It is not a placebo or a minor add-on for people who are barely uncomfortable. For the autonomic symptoms of withdrawal, it performs about as well as a benzodiazepine.
The key word in those studies, though, is “moderate uncomplicated.” The patients enrolled did not have a history of withdrawal seizures, were not showing signs of delirium, and were not at high risk for the most severe forms of withdrawal. For that population, propranolol looked quite good. The problem is that withdrawal is unpredictable, and the population of people who need treatment extends well beyond mild-to-moderate cases.
Why Propranolol Cannot Be Used Alone
A large meta-analysis published in JAMA that reviewed the evidence for various withdrawal medications concluded that beta-blockers reduce the overall severity of withdrawal, but the evidence is inadequate to determine whether they prevent delirium or seizures. The same analysis recommended that beta-blockers not be used as the sole treatment for alcohol withdrawal and instead be reserved as adjunctive therapy alongside medications with proven seizure protection.6JAMA. Pharmacological Management of Alcohol Withdrawal: A Meta-analysis and Evidence-Based Practice Guideline
This is the central limitation of propranolol. Seizures and delirium tremens are the life-threatening complications of withdrawal, and they arise from the excitatory-inhibitory imbalance in the brain, not from the norepinephrine surge. Propranolol does not address that imbalance. Benzodiazepines do, which is why they remain the standard of care.7PubMed Central. Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond A person on propranolol alone might feel much calmer and have a normal heart rate while still being at risk for a grand mal seizure. The drug treats the surface symptoms without touching the deeper neurological instability. That is a dangerous combination because it can create a false sense of security for both the patient and their clinician.
In practical terms, this means propranolol shows up in treatment plans as a helper medication. A patient receiving a benzodiazepine taper might also get propranolol to bring down a persistently elevated heart rate or to control tremor that the benzodiazepine alone is not fully managing. Some clinicians use it specifically for people whose anxiety remains intense even after adequate benzodiazepine dosing, since propranolol works through a completely different pathway and can add benefit that more benzodiazepine might not.
Cardiovascular Responses Are Different During Active Withdrawal
One thing that makes prescribing propranolol during withdrawal trickier than in other settings is that the body responds to the drug differently when it is in a state of withdrawal versus when it has recovered. A study measuring cardiovascular effects of propranolol in alcohol-dependent patients found significant differences in how much the drug lowered heart rate and blood pressure during withdrawal compared to during remission. The most important factor shaping these responses was the patient’s baseline blood pressure and heart rate before the drug was given.8PubMed. Cardiovascular effects of propranolol in patients with alcohol dependence during withdrawal
This makes intuitive sense if you think about it. During active withdrawal, the sympathetic nervous system is running at full throttle. Blood pressure and heart rate are already high, so a drug that dampens that system has a lot of room to bring things down, sometimes more than intended. A dose of propranolol that barely nudges your heart rate in normal circumstances might cause a steep drop when your body is already in overdrive. For clinicians, this means careful monitoring, especially in the early hours and days of withdrawal when autonomic instability is at its peak. For patients, it means propranolol dosing during withdrawal is not the same as the dose you might take for a performance anxiety situation or migraine prevention.
People with already low blood pressure, those who are dehydrated from days of drinking without eating, or those with underlying heart conditions face extra risk. Withdrawal itself can cause dangerous swings in vital signs, and adding a blood-pressure-lowering drug to that mix requires clinical oversight. This is one reason propranolol for withdrawal is a monitored-setting medication, not something to self-prescribe.
Propranolol’s Separate Role in Reducing Alcohol Craving
An entirely different line of research has explored propranolol not for managing acute withdrawal symptoms but for reducing the craving for alcohol in people with alcohol use disorder. The mechanism is unrelated to what happens during withdrawal. Researchers have found that when a person recalls an alcohol-associated memory (like the sensory cues tied to drinking), that memory briefly becomes unstable and must be “reconsolidated” back into long-term storage. If propranolol is administered during that window of instability, the emotional charge attached to the memory appears to weaken.
A pilot randomized controlled trial tested this by having people with substance dependence recall their drug-related memories and then receive either propranolol or placebo. The group given propranolol showed a large reduction in craving, while the placebo group showed essentially no change.9PubMed. Reactivating addiction-related memories under propranolol to reduce craving: A pilot randomized controlled trial A more recent study specifically focused on alcohol-associated memories confirmed that propranolol given after memory retrieval could disrupt the reconsolidation of those memories and reduce alcohol craving.10PubMed Central. Effect of inhibition of reactivated alcohol-associated memories with propranolol on alcohol craving
This is still early-stage research with small sample sizes, and nobody is using this as a standard treatment yet. But the concept is intriguing because it targets a completely different problem from withdrawal. Craving often persists long after the acute withdrawal phase is over and is one of the major drivers of relapse. If propranolol can weaken the learned associations between environmental cues and the desire to drink, it could eventually have a role in longer-term recovery that has nothing to do with managing tremor or tachycardia. For now, consider it a promising lead rather than a proven approach.
How Propranolol Compares to Other Non-Benzodiazepine Options
Propranolol is not the only alternative to benzodiazepines that clinicians reach for during withdrawal. Several other non-benzodiazepine medications have been studied, and some have accumulated stronger evidence than propranolol has.
A meta-analysis comparing non-benzodiazepine treatments found that gabapentin performed better than certain benzodiazepines at reducing withdrawal severity scores, as did carbamazepine.11European Journal of Clinical Pharmacology. Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management A separate systematic review graded the overall certainty of the evidence and found that gabapentin had a moderate level of evidence supporting its use against standard benzodiazepine treatment, while the evidence for other alternatives like carbamazepine, baclofen, and valproate was rated lower.12Oxford Academic (Alcohol and Alcoholism). The Effectiveness of Non-Benzodiazepine, Non-Barbiturate Medications for Alcohol Withdrawal Syndrome: A Rapid Systematic Review
Gabapentin has a particular advantage: it also has anticonvulsant properties, meaning it can address the seizure risk that propranolol cannot. This makes gabapentin a more versatile alternative to benzodiazepines in mild-to-moderate cases, particularly in outpatient settings where the lower abuse potential compared to benzodiazepines is attractive. Carbamazepine, another anticonvulsant, has been widely used in European countries for withdrawal management for decades, though it has gained less traction in the United States.
Clonidine and lofexidine deserve a mention because, like propranolol, they target the noradrenergic system. Instead of blocking the receptors that norepinephrine acts on, they reduce norepinephrine release from the brain. The same JAMA meta-analysis that cautioned against beta-blocker monotherapy applied the same warning to clonidine.6JAMA. Pharmacological Management of Alcohol Withdrawal: A Meta-analysis and Evidence-Based Practice Guideline The systematic review rated the evidence for clonidine and lofexidine as very low.12Oxford Academic (Alcohol and Alcoholism). The Effectiveness of Non-Benzodiazepine, Non-Barbiturate Medications for Alcohol Withdrawal Syndrome: A Rapid Systematic Review So propranolol is not uniquely disadvantaged among the adrenergic drugs; the entire class shares the same gap in seizure and delirium protection.
Where Propranolol Fits in a Realistic Treatment Plan
If you or someone you know is dealing with alcohol withdrawal, the honest picture is that propranolol occupies a specific and limited niche. It excels at controlling the autonomic symptoms that make withdrawal physically miserable, and it does so through a mechanism completely different from benzodiazepines. That makes it useful as a complement, letting clinicians use less of a benzodiazepine while still getting the heart rate and blood pressure under control. In settings where symptom-triggered dosing protocols are used (where medication is given only when symptoms cross a certain threshold), propranolol can reduce the number of benzodiazepine doses a person needs.
But propranolol should never be the only medication someone relies on during withdrawal, especially if there is any history of withdrawal seizures, prior delirium tremens, heavy daily consumption, or medical comorbidities. The consequences of an unprotected seizure are too severe. For mild cases where the risk of seizure is assessed as low, some clinicians do feel comfortable combining propranolol with non-benzodiazepine anticonvulsants like gabapentin, avoiding benzodiazepines altogether. That approach is gaining traction but remains somewhat outside the mainstream consensus, which still leans on benzodiazepines as the foundation.
The Overlap With PTSD and Anxiety Disorders
Propranolol has a long independent history of use for anxiety-related conditions, including PTSD, social anxiety, and performance anxiety. Many people going through alcohol withdrawal also have co-occurring anxiety disorders or PTSD, and this overlap makes propranolol an appealing choice for clinicians treating both problems simultaneously. The noradrenergic system is implicated in both PTSD symptoms and alcohol withdrawal, and medications that target it can potentially address symptoms in both conditions at once.13PubMed Central. Pharmacotherapy for Co-Occurring Alcohol Use Disorder and Post-Traumatic Stress Disorder: Targeting the Opioidergic, Noradrenergic, Serotonergic, and GABAergic/Glutamatergic Systems
That said, current medications targeting the noradrenergic system for the combined treatment of alcohol use disorder and PTSD have shown only modest results so far. The research is active and ongoing, with newer targets within these systems being explored, but no one has found a single medication that robustly treats both conditions. For someone with both PTSD and alcohol dependence going through withdrawal, propranolol might help bridge the acute phase while longer-term treatments for both conditions are established, but it is far from a complete solution for either.
The broader point is that propranolol’s usefulness in alcohol withdrawal depends heavily on what else is going on with the patient. For someone whose primary suffering during withdrawal is the physical hyperarousal, a pounding heart, shaking hands, drenching sweats, propranolol addresses those complaints directly and effectively. For someone at risk for seizures or delirium, it is a side dish, not the main course. And for someone whose bigger struggle is the craving and psychological pull to drink again, the memory reconsolidation research hints at a future role for propranolol, but not one that is ready for routine clinical use today.